Earnings History Data for Chimerix, Inc. (CMRX) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Chimerix, Inc.

Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
02-03-2023	PM	7:00 AM ET (Mar 2)	CMRX	Chimerix, Inc.	138.23	-0.24	-0.24	-0.45	Chimerix GAAP EPS of -$0.24 in-line, revenue of $0.8M beats by $0.22M [3/2/2023 7:04 AM]	1.70	0.10 (6.60%)	1.68	0.09 (5.66%)	1.27 - 6.08	1,300,491	710,000	126,934
Chimerix Q4 2022 Earnings Preview [3/1/2023 12:56 PM] Chimerix GAAP EPS of -$0.24 in-line, revenue of $0.8M beats by $0.22M [3/2/2023 7:04 AM]
03-11-2022	PM	6:30 AM ET (Nov 3)	CMRX	Chimerix, Inc.	164.73	2.75	2.10	-0.21	Chimerix GAAP EPS of $2.75 beats by $0.65, revenue of $32.56M [11/3/2022 7:25 AM]	1.82	-0.04 (-2.27%)	1.98	0.12 (6.53%)	1.27 - 7.42	1,085,667	1,000,000	887,046
Chimerix Q3 2022 Earnings Preview [11/2/2022 12:30 PM] Chimerix GAAP EPS of $2.75 beats by $0.65, revenue of $32.56M [11/3/2022 7:25 AM] Chimerix gains on regulatory updates for cancer therapy [11/3/2022 9:11 AM]
08-08-2022	AH	After the close (Aug 8)	CMRX	Chimerix, Inc.	160.88	-0.27	-0.24	-0.21	Chimerix GAAP EPS of -$0.27 misses by $0.03, revenue of $0.44M beats by $0.41M [8/8/2022 4:45 PM]	2.46	0.10 (4.03%)	2.36	0.0 (0.00%)	1.27 - 7.42	6,195,444	11,200,000	422,578
Chimerix GAAP EPS of -$0.27 misses by $0.03, revenue of $0.44M beats by $0.41M [8/8/2022 4:45 PM] Chimerix Reports Second Quarter 2022 Financial Results and Provides Operational Update [Aug-08-22 04:01PM] Chimerix Appoints Christopher L. Jordan as Vice President, Regulatory Affairs [Aug-08-22 07:00AM]
16-05-2022	PM	7:00 AM ET (May 16)	CMRX	Chimerix, Inc.	358.49	-0.28	-0.35	-0.18	Chimerix GAAP EPS of -$0.28 beats by $0.07, revenue of $0.02M beats by $0.02M [5/16/2022 7:01 AM]	1.62	-2.61 (-61.67%)	1.96	-2.28 (-53.77%)	1.60 - 9.29	30,466,660	1,030,000	6,242,217
Chimerix GAAP EPS of -$0.28 beats by $0.07, revenue of $0.02M beats by $0.02M [5/16/2022 7:01 AM] Chimerix stock slumps ~37% on Emergent acquiring rights to smallpox therapy Tembexa [5/16/2022 7:23 AM] Emergent BioSolutions to Acquire from Chimerix its Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages [May-16-22 06:32AM] Chimerix Announces Sale of TEMBEXA to Emergent BioSolutions for up to $337.5 Million plus Royalties [May-16-22 06:30AM] Chimerix stock surges after deal to sell smallpox treatment Tembexa for up to $337.5 million, plus royalties [May-16-22 06:43AM] Chimerix Reports First Quarter 2022 Financial Results and Provides Operational Update [May-16-22 07:00AM] JetBlue Goes Hostile on Spirit, but This Biopharma's Getting Hit Hard [May-16-22 09:11AM] Here's Why Chimerix Stock Is Imploding Today [May-16-22 10:59AM] Gaithersburg's Emergent BioSolutions to acquire smallpox drug from Chimerix [May-16-22 12:05PM] Chimerix Shares Plummet After Divesting Its Only Marketed Product For Over $300M [May-16-22 09:54AM] Chimerix (CMRX) Q1 2022 Earnings Call Transcript [May-16-22 02:00PM]
01-03-2022	PM	7:05 AM ET (Mar 1)	CMRX	Chimerix, Inc.	489.04	-0.45	-0.11	-0.19	Chimerix GAAP EPS of -$0.45 misses by $0.28, revenue of $0.05M misses by $18.01M [3/1/2022 7:07 AM]	5.56	-0.08 (-1.42%)	5.75	0.11 (1.95%)	4.75 - 10.89	741,924	810,000	7,354
Chimerix Q4 2021 Earnings Preview [2/28/2022 1:44 PM] Chimerix GAAP EPS of -$0.45 misses by $0.28, revenue of $0.05M misses by $18.01M [3/1/2022 7:07 AM] Chimerix to Present at Cowen and Company 42nd Annual Health Care Conference [Feb-28-22 07:00AM] Chimerix Reports Fourth Quarter and Year End 2021 Financial Results and Provides Operational Update [Mar-01-22 07:00AM] Chimerix (CMRX) Reports Q4 Loss, Lags Revenue Estimates [Mar-01-22 08:45AM] Chimerix (CMRX) Q4 2021 Earnings Call Transcript [Mar-01-22 06:30PM]
04-11-2021	PM	7:00 AM ET (Nov 4)	CMRX	Chimerix, Inc.	470.92	-0.21	-0.21	-0.18	Chimerix EPS in-line, misses on revenue [11/4/2021 7:20 AM]	6.10	0.22 (3.74%)	6.10	0.0 (0.00%)	2.73 - 11.57	2,107,532	780,000	491
Chimerix Q3 2021 Earnings Preview [11/3/2021 9:55 AM] Chimerix EPS in-line, misses on revenue [11/4/2021 7:20 AM] Chimerix shares slide 27% after Q3 topline miss, cash position update [11/4/2021 8:06 AM] Chimerix Reports Third Quarter 2021 Financial Results and Provides Operational Update [Nov-04-21 07:05AM] Chimerix Announces Positive Topline Results for ONC201 in Recurrent H3 K27M-mutant Glioma [Nov-04-21 07:00AM] Chimerix (CMRX) Reports Q3 Loss, Lags Revenue Estimates [Nov-04-21 10:25AM] Chimerix (CMRX) Q3 2021 Earnings Call Transcript [Nov-04-21 08:03PM]
05-08-2021	PM	7:00 AM ET (Aug 5)	CMRX	Chimerix, Inc.	571.58	-0.21	-0.19	-0.16	Chimerix EPS misses by $0.02, beats on revenue [8/5/2021 7:10 AM]	6.71	0.23 (3.55%)	6.55	0.07 (1.08%)	2.22 - 11.57	1,114,952	450,000	1,000
Chimerix EPS misses by $0.02, beats on revenue [8/5/2021 7:10 AM] Chimerix Reports Second Quarter 2021 Financial Results and Provides Operational Update [Aug-05-21 07:00AM]
06-05-2021	PM	7:00 AM ET (May 6)	CMRX	Chimerix, Inc.	770.26	-0.18	-0.48	-0.17	Chimerix EPS misses by $0.73, beats on revenue [5/6/2021 7:07 AM]	8.49	-0.23 (-2.64%)	8.49	0.0 (0.00%)	2.22 - 11.57	556,658	370,000	3,972
Chimerix EPS misses by $0.73, beats on revenue [5/6/2021 7:07 AM] Chimerix (CMRX) Sees Hammer Chart Pattern: Time to Buy? [May-05-21 06:40AM] Chimerix Reports First Quarter 2021 Financial Results and Provides Operational Update [May-06-21 07:00AM]
25-02-2021	PM	7:00 AM ET (Feb 25)	CMRX	Chimerix, Inc.	743.55	-0.19	-0.20	-0.06	Chimerix EPS beats by $0.01, misses on revenue [2/25/2021 7:11 AM]	10.68	0.50 (4.91%)	10.00	-0.18 (-1.77%)	1.19 - 11.57	825,349	600,190	30,767
Chimerix EPS beats by $0.01, misses on revenue [2/25/2021 7:11 AM] The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants [Feb-25-21 08:08AM] Chimerix Reports Promising Topline Results from First Cohort of a Randomized COVID-19 Trial with DSTAT [Feb-25-21 07:00AM] Chimerix Reports Fourth Quarter and Year End 2020 Financial Results and Provides Operational Update [Feb-25-21 07:00AM] Chimerix, Inc. to Host Earnings Call [Feb-25-21 06:30AM]
05-11-2020	PM	7:00 AM ET (Nov 5)	CMRX	Chimerix, Inc.	175.40	-0.18	-0.17	-0.15	Chimerix EPS misses by $0.01, beats on revenue [11/5/2020 7:10 AM]	3.09	0.03 (0.98%)	3.18	0.12 (3.92%)	1.19 - 3.88	923,226	283,595	14,121

10-08-2020	PM	7:00 AM ET (Aug 10)	CMRX	Chimerix, Inc.	200.03	-0.16	-0.17	-0.35	Chimerix EPS beats by $0.01, misses on revenue [8/10/2020 7:02 AM]	3.22	-0.19 (-5.57%)	3.41	0.0 (0.00%)	1.19 - 3.88	352,742	457,291	52,239